<DOC>
	<DOCNO>NCT00006012</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , , radiation therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose thoracic radiotherapy administer cisplatin , etoposide , amifostine precede followed topotecan paclitaxel patient limited stage small cell lung cancer ( phase I close accrual 5/27/2004 ) . - Determine two-year survival patient population treat regimen . - Determine two-year , progression-free local control rate patient population treat regimen . - Assess tolerability treatment regimen patient . - Determine antitumor activity regimen patient . - Determine overall survival overall time progression patient population treat regimen . OUTLINE : This multicenter , dose-escalation study thoracic radiotherapy ( TRT ) . Patients receive topotecan IV day 1-5 paclitaxel IV 3 hour day 5 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin 24 hour last dose chemotherapy continue blood count recover . Treatment repeat every 3 week 2 course . After 2 course topotecan paclitaxel , patient undergo TRT twice daily 5 consecutive day 5 week . During TRT , patient receive cisplatin IV , oral etoposide , amifostine SC daily prior TRT . At 4 week completion TRT , patient receive 2 additional course topotecan , paclitaxel , G-CSF every 3 week follow prophylactic cranial irradiation . Cohorts 3-6 patient receive escalate dos TRT maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity ( phase I close accrual 5/27/2004 ) . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 3-73 patient accrue study ( phase I close accrual 5/27/2004 ) .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Limited disease confine one hemithorax , ipsilateral supraclavicular fossa , encompassable within tolerable thoracic radiotherapy field Minimal pleural effusion ( i.e. , blunt costophrenic angle chest xray small effusion CT scan ) allow Measurable disease At least one lesion accurately measure least 1 dimension long diameter least 20 mm PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease Pulmonary : FEV_1 least 40 % predict AND least 1 liter Other : No uncontrolled infection No severe underlie diseases No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer noninvasive carcinoma ( carcinoma situ ) No grade 2 great peripheral neuropathy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No hypersensitivity E.coliderived proteins , filgrastim ( GCSF ) , excipients GCSF PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No prior hemithorax radiotherapy Surgery Not specify Other No prior therapy small cell lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>